

<http://hdl.handle.net/1765/116703>



# List of publications



## LIST OF PUBLICATIONS

47. **Oemrawsingh RM**, Akkerhuis KM, de Mulder M, Umans VA, Kietselaer B, Schotborgh C, Ronner E, Lenderink T, Liem A, Haitsma D, van der Harst P, Asselbergs FW, Maas A, Oude Ophuis AJ, Ilmer B, Dijkgraaf R, de Winter RJ, Kie The SH, Wardeh AJ, Hermans W, Cramer E, van Schaik RH, Hoefler IE, Doevendans PA, Simoons ML, Boersma E; BIOMArCS Investigators. *High-Frequency Biomarker Measurements of Troponin, NT-proBNP, and C-Reactive Protein for Prediction of New Coronary Events After Acute Coronary Syndrome*. **Circulation**. 2019 Jan 2;139(1):134-136.
46. Vroegindewey MM, **Oemrawsingh RM**, Kardys I, Asselbergs FW, van der Harst P, Oude Ophuis AJ, Etienne Cramer G, Maas A, Hong Kie The S, Wardeh AJ, Mouthaan H, Boersma E, Akkerhuis KM. *The temporal pattern of immune and inflammatory proteins prior to a recurrent coronary event in post-acute coronary syndrome patients*. **Biomarkers**. 2018 Dec 4:1-7.
45. Schuurman AS, Vroegindewey MM, Kardys I, Oemrawsingh RM, Garcia-Garcia HM, van Geuns RJ, Regar E, Van Mieghem NM, Ligthart J, Serruys PW, Boersma E, Akkerhuis KM. *Prognostic Value of Intravascular Ultrasound in Patients With Coronary Artery Disease*. **J Am Coll Cardiol**. 2018 Oct 23;72(17):2003-2011.
44. Anroedh SS, Akkerhuis KM, **Oemrawsingh RM**, Garcia-Garcia HM, Brankovic M, Regar E, van Geuns RJ, Serruys PW, Daemen J, van Mieghem NM, Boersma E, Kardys I. Associations of 26 Circulating Inflammatory and Renal Biomarkers with Near-Infrared Spectroscopy and Long-term Cardiovascular Outcome in Patients Undergoing Coronary Angiography (ATHEROREMO-NIRS Substudy). **Curr Atheroscler Rep**. 2018 Sep 14;20(10):52.
43. Ijsselmuiden AJJ, Zwaan EM, **Oemrawsingh RM**, Bom MJ, Dankers FJWM, de Boer MJ, Camaro C, van Geuns RJM, Daemen J, van der Heijden DJ, Jukema JW, Kraaijeveld AO, Meuwissen M, Schölzel BE, Pundziute G, van der Harst P, van Ramshorst J, Dirksen MT, Zivelonghi C, Agostoni P, van der Heyden JAS, Wykrzykowska JJ, Scholte MJ, Nef HM, Kofflard MJM, van Royen N, Alings M, Kedhi E. *Appropriate use criteria for optical coherence tomography guidance in percutaneous coronary interventions: Recommendations of the working group of interventional cardiology of the Netherlands Society of Cardiology*. **Neth Heart J**. 2018 Aug 31.
42. Van den Berg VJ, Haskard DO, Fedorowski A, Hartley A, Kardys I, Caga-Anan M, Akkerhuis KM, **Oemrawsingh RM**, van Geuns RJ, de Jaegere P, van Mieghem N, Regar E, Ligthart JMR, Umans VAWM, Serruys PW, Melander O, Boersma E, Khamis RY. *IgM anti-malondialdehyde low density lipoprotein antibody levels indicate coronary heart disease and necrotic core characteristics in the Nordic Diltiazem (NORDIL) study and the Integrated Imaging and Biomarker Study 3 (IBIS-3)*. **EBioMedicine**. 2018 Aug 18. pii: S2352-3964(18)30309-8.

41. Vroegindewey MM, Schuurman AS, **Oemrawsingh RM**, van Geuns RJ, Kardys I, Ligthart J, Daemen J, Boersma E, Serruys PW, Akkerhuis KM. *SYNTAX score II predicts long-term mortality in patients with one- or two-vessel disease*. **PLoS One**. 2018 Jul 2; 13(7):e0200076.
40. Anroedh S, Hilvo M, Akkerhuis KM, Kauhanen D, Koistinen K, **Oemrawsingh R**, Serruys P, van Geuns RJ, Boersma E, Laaksonen R, Kardys I. *Plasma concentrations of molecular lipid species predict long-term clinical outcome in coronary artery disease patients*. **J Lipid Res**. 2018 Sep;59(9):1729-1737.
39. Vroegindewey MM, Schuurman AS, Kardys I, Anroedh SS, **Oemrawsingh RM**, Ligthart J, Garcia-Garcia HM, van Geuns RM, Regar E, Van Mieghem NM, Serruys PW, Boersma E, Akkerhuis M. *SYNTAX score in relation to intravascular ultrasound and near-infrared spectroscopy for the assessment of atherosclerotic burden in patients with coronary artery disease*. **EuroIntervention**. 2018 Mar 13. pii:EIJ-D-17-00827
38. Schuurman AS, Vroegindewey M, Kardys I, **Oemrawsingh RM**, Cheng JM, de Boer S, Garcia-Garcia HM, van Geuns RJ, Regar ES, Daemen J, van Mieghem NM, Serruys PW, Boersma E, Akkerhuis KM. *Near-infrared spectroscopy-derived lipid core burden index predicts adverse cardiovascular outcome in patients with coronary artery disease during long-term follow-up*. **Eur Heart J**. 2018 Jan 21;39(4):295-302.
37. **Oemrawsingh RM**, Akkerhuis KM, Umans VA, Kietselaer B, Schotborgh C, Ronner E, Lenderink T, Liem A, Haitsma D, Van der Harst P, Asselbergs FW, Maas A, Oude Ophuis AJ, Ilmer B, Dijkgraaf R, De Winter R-J, The SHK, Wardeh AJ, Hermans W, Cramer E, Van Schaik RH, Hofer IE, Doevendans PA, Simoons ML, Boersma E. *Cohort profile of BIOMArCS: The BIOMarker study to identify the Acute risk of a Coronary Syndrome—a prospective multicentre biomarker study conducted in the Netherlands*. **BMJ Open** 2016 Dec 23;6(12):e012929
36. Buljubasic N, Akkerhuis KM, Cheng JM, **Oemrawsingh RM**, Garcia-Garcia HM, de Boer SP, Regar E, van Geuns RM, Serruys PW, Boersma E, Kardys I. *Fibrinogen in relation to degree and composition of coronary plaque on intravascular ultrasound in patients undergoing coronary angiography*. **Coron Artery Dis**. 2017 Jan;28(1):23-32.
35. Brankovic M, Akkerhuis KM, Buljubasic N, Cheng JM, **Oemrawsingh RM**, Garcia-Garcia HM, Regar E, Serruys PW, van Geuns RJ, Boersma E, Kardys I. *Plasma cystatin C and neutrophil gelatinase-associated lipocalin in relation to coronary atherosclerosis on intravascular ultrasound and cardiovascular outcome: Impact of kidney function (ATHEROREMO-IVUS study)*. **Atherosclerosis**. 2016 Nov;254:20-27.
34. **Oemrawsingh RM**, Garcia-Garcia HM, van Geuns RJ, Lenzen MJ, Simsek C, de Boer SP, Van Mieghem NM, Regar E, de Jaegere PP, Akkerhuis KM, Ligthart JM, Zijlstra F, Serruys PW, Boersma E. *Integrated Biomarker and Imaging Study 3 (IBIS-3) to assess the ability of rosuvastatin to decrease necrotic core in coronary arteries*. **EuroIntervention**. 2016 Aug 20;12(6):734-9.

33. Buljubasic N, **Oemrawsingh RM**, Smeets MB, Cheng JM, Regar E, van Geuns RJ, Serruys PW, Boersma E, Akkerhuis KM, Kardys I, Arslan F. *Haptoglobin polymorphism in relation to coronary plaque characteristics on radiofrequency intravascular ultrasound and near-infrared spectroscopy in patients with coronary artery disease*. **Int J Cardiol**. 2016 Oct 15;221:682-7.
32. **Oemrawsingh RM**, Akkerhuis KM, Van Vark LC, Redekop WK, Rudez G, Remme WJ, Bertrand ME, Fox KM, Ferrari R, Danser AH, de Maat M, Simoons ML, Brugts JJ, Boersma E; PERGENE investigators. *Individualized Angiotensin-Converting Enzyme (ACE)-Inhibitor Therapy in Stable Coronary Artery Disease Based on Clinical and Pharmacogenetic Determinants: The PERindopril GENetic (PERGENE) Risk Model*. **J Am Heart Assoc**. 2016 Mar 28;5(3):e002688.
31. **Oemrawsingh RM**, Cheng JM, García-García HM, Kardys I, van Schaik RH, Regar E, van Geuns RJ, Serruys PW, Boersma E, Akkerhuis KM. *High-sensitivity Troponin T in relation to coronary plaque characteristics in patients with stable coronary artery disease; results of the ATHEROREMO-IVUS study*. **Atherosclerosis**. 2016 Apr;247:135-41.
30. **Oemrawsingh RM\***, Cheng JM\*, Garcia-Garcia HM, Boersma E, van Geuns RJ, Serruys PW, Kardys I, Akkerhuis KM. PCSK9 in relation to coronary plaque inflammation: Results of the ATHEROREMO-IVUS study. **Atherosclerosis**. 2016 May;248:117-22.  
\* = equal contribution
29. Buljubasic N, Akkerhuis KM, de Boer SP, Cheng JM, Garcia-Garcia HM, Lenzen MJ, **Oemrawsingh RM**, Battes LC, Rijndertse M, Regar E, Serruys PW, van Geuns RJ, Boersma E, Kardys I. *Smoking in Relation to Coronary Atherosclerotic Plaque Burden, Volume and Composition on Intravascular Ultrasound*. **PLoS One**. 2015 Oct 22;10(10):e0141093.
28. Cheng JM, Suoniemi M, Kardys I, Vihervaara T, de Boer SP, Akkerhuis KM, Sysi-Aho M, Ekroos K, Garcia-Garcia HM, **Oemrawsingh RM**, Regar E, Koenig W, Serruys PW, van Geuns RJ, Boersma E, Laaksonen R. *Plasma concentrations of molecular lipid species in relation to coronary plaque characteristics and cardiovascular outcome: Results of the ATHEROREMO-IVUS study*. **Atherosclerosis**. 2015 Dec;243(2):560-566.
27. Eindhoven JA, van den Bosch AE, **Oemrawsingh RM**, Baggen VJ, Kardys I, Cuypers JA, Witsenburg M, van Schaik RH, Roos-Hesselink JW, Boersma E. *Release of growth-differentiation factor 15 and associations with cardiac function in adult patients with congenital heart disease*. **Int J Cardiol**. 2015 Sep 14;202:246-251.
26. **Oemrawsingh RM**, Cheng JM, Akkerhuis KM, Kardys I, Degertekin M, van Geuns RJ, Daemen J, Boersma E, Serruys PW, van Domburg RT. *High-sensitivity C-reactive protein predicts 10-year cardiovascular outcome after percutaneous coronary intervention*. **EuroIntervention** 2016 Jun 20;12(3):345-51
25. van der Leeuw J, **Oemrawsingh RM**, van der Graaf Y, Brugts JJ, Deckers JW, Bertrand M, Fox K, Ferrari R, Remme WJ, Simoons ML, Boersma E, Visseren FL. *Prediction of*

- absolute risk reduction of cardiovascular events with perindopril for individual patients with stable coronary artery disease – results from EUROPA. Int J Cardiol.* 2015 Mar 1; 182:194-9.
24. **Oemrawsingh RM**, Cheng JM, García-García HM, van Geuns RJ, de Boer SP, Simsek C, Kardys I, Lenzen MJ, van Domburg RT, Regar E, Serruys PW, Akkerhuis KM, Boersma E; ATHEROREMO-NIRS Investigators. *Near-infrared spectroscopy predicts cardiovascular outcome in patients with coronary artery disease. J Am Coll Cardiol.* 2014 Dec 16; 64(23):2510-8.
  23. Sonneveld MA, Cheng JM, **Oemrawsingh RM**, de Maat MP, Kardys I, Garcia-Garcia HM, van Geuns RJ, Regar E, Serruys PW, Boersma E, Akkerhuis KM, Leebeek FW. *Von Willebrand factor in relation to coronary plaque characteristics and cardiovascular outcome. Results of the ATHEROREMO-IVUS study. Thromb Haemost.* 2015 Mar;113(3): 577-84.
  22. Battes LC, Akkerhuis KM, Cheng JM, Garcia-Garcia HM, **Oemrawsingh RM**, de Boer SP, Regar E, van Geuns RJ, Serruys PW, Boersma E, Kardys I. *Circulating acute phase proteins in relation to extent and composition of coronary atherosclerosis and cardiovascular outcome: results from the ATHEROREMO-IVUS study. Int J Cardiol.* 2014 Dec 20;177(3):847-53.
  21. **Oemrawsingh RM\***, Cheng JM\*, Garcia-Garcia HM, Akkerhuis KM, Kardys I, de Boer SP, Langstraat JS, Regar E, van Geuns RJ, Serruys PW, Boersma E. *Relation of C-Reactive Protein to Coronary Plaque Characteristics on Grayscale, Radiofrequency Intravascular Ultrasound, and Cardiovascular Outcome in Patients With Acute Coronary Syndrome or Stable Angina Pectoris (from the ATHEROREMO-IVUS Study). Am J Cardiol.* 2014 Nov 15;114(10):1497-503.
- \* = equal contribution
20. Cheng JM, **Oemrawsingh RM**, Akkerhuis KM, Garcia-Garcia HM, de Boer SP, Battes LC, Buljubasic N, Lenzen MJ, de Jaegere PP, van Geuns RJ, Serruys PW, Kardys I, Boersma E. *Circulating chemokines in relation to coronary plaque characteristics on radiofrequency intravascular ultrasound and cardiovascular outcome. Biomarkers.* 2014 Nov;19(7):611-9.
  19. Battes LC, Cheng JM, **Oemrawsingh RM**, Boersma E, Garcia-Garcia HM, de Boer SP, Buljubasic N, Mieghem NA, Regar E, Geuns RJ, Serruys PW, Akkerhuis KM, Kardys I. *Circulating cytokines in relation to the extent and composition of coronary atherosclerosis: results from the ATHEROREMO-IVUS study. Atherosclerosis.* 2014 Sep;236(1): 18-24
  18. Cheng JM, Akkerhuis KM, Meilhac O, **Oemrawsingh RM**, Garcia-Garcia HM, van Geuns RJ, Piquer D, Merle D, du Paty E, Galéa P, Jaisser F, Rossignol P, Serruys PW, Boersma E, Fareh J, Kardys I. *Circulating osteoglycin and NGAL/MMP9 complex con-*

- centrations predict 1-year major adverse cardiovascular events after coronary angiography. **Arterioscler Thromb Vasc Biol.** 2014 May;34(5):1078-84.
17. Cheng JM, Garcia-Garcia HM, de Boer SP, Kardys I, Heo JH, Akkerhuis KM, **Oemrawsingh RM**, van Domburg RT, Ligthart J, Witberg KT, Regar E, Serruys PW, van Geuns RJ, Boersma E. *In vivo detection of high-risk coronary plaques by radiofrequency intravascular ultrasound and cardiovascular outcome: results of the ATHEROREMO-IVUS study.* **Eur Heart J.** 2014 Mar;35(10):639-47.
  16. de Boer SP, van Leeuwen MA, Cheng JM, **Oemrawsingh RM**, van Geuns RJ, Serruys PW, Boersma E, Lenzen MJ. *Trial participation as a determinant of clinical outcome: Differences between trial-participants and Every Day Clinical Care patients in the field of interventional cardiology.* **Int J Cardiol.** 2013 Nov 15;169(4):305-10.
  15. de Boer SP, Cheng JM, Garcia-Garcia HM, **Oemrawsingh RM**, van Geuns RJ, Regar E, Zijlstra F, Laaksonen R, Halperin E, Kleber ME, Koenig W, Boersma E, Serruys PW. *Relation of genetic profile and novel circulating biomarkers with coronary plaque phenotype as determined by intravascular ultrasound: rationale and design of the ATHEROREMO-IVUS study.* **EuroIntervention.** 2014 Dec;10(8):953-60.
  14. de Mulder M, Umans VA, Cornel JH, van der Zant FM, Stam F, **Oemrawsingh RM**, Akkerhuis KM, Boersma E. *Intensive Glucose Regulation in Hyperglycemic Acute Coronary Syndrome: Results of the Randomized BIOMarker Study to Identify the Acute Risk of a Coronary Syndrome-2 (BIOMArCS-2) Glucose Trial.* **JAMA Intern Med.** 2013 Nov 11; 173(20):1896-904.
  13. Panasewicz A, Pedersen SS, Veenhuis SJ, **Oemrawsingh RM**, van der Giessen WJ, van Geuns RJ, Regar E, de Jaegere PP, Serruys PW, van Domburg RT. *Health-related quality of life in the elderly three years after percutaneous coronary intervention.* **EuroIntervention.** 2013 Jul 22;9(3):373-81.
  12. García-García HM, **Oemrawsingh RM**, Brugaletta S, Vranckx P, Shannon J, Davies R, Boersma E, Serruys PW. *Darapladib effect on circulating high sensitive troponin in patients with acute coronary syndromes.* **Atherosclerosis.** 2012 Nov;225(1):142-7.
  11. De Boer SPM, **Oemrawsingh RM**, Lenzen MJ, Van Mieghem NM, Schultz C, Akkerhuis KM, Van Leeuwen MAH, Zijlstra F, Van Domburg RT, Serruys PWJC, Boersma E (on behalf of the interventional cardiologists of the Thoraxcenter 2000–2009) *Primary PCI during off-hours is not related to increased mortality* **Eur Heart J: Acute Cardiovascular Care** April 2012 1: 33-39.
  10. Eindhoven JA, Onuma Y, **Oemrawsingh RM**, Daemen J, van Nierop JW, de Jaegere PP, Boersma E, Serruys PW, van Domburg RT. *Long-term outcome after statin treatment in routine clinical practice: results from a prospective PCI cohort study.* **EuroIntervention.** 2012 Apr;7(12):1420-7.
  9. Kardys I, **Oemrawsingh RM**, Kay IP, Jones GT, McCormick SP, Daemen J, Van Geuns RJ, Boersma E, Van Domburg RT, Serruys PW. *Lipoprotein(a), interleukin-10, C-reactive*

- protein, and 8-year outcome after percutaneous coronary intervention. **Clin Cardiol.** 2012 Aug;35(8):482-9.
8. Schenkeveld L, Magro M, **Oemrawsingh RM**, Lenzen M, de Jaegere P, van Geuns RJ, Serruys PW, van Domburg RT. *The influence of optimal medical treatment on the 'obesity paradox', body mass index and long-term mortality in patients treated with percutaneous coronary intervention: a prospective cohort study.* **BMJ Open.** 2012 Feb 9;2:e000535.
  7. Battes LC, Pedersen SS, **Oemrawsingh RM**, van Geuns RJ, Al Amri I, Regar E, de Jaegere PP, Serruys P, van Domburg RT. *Beta blocker therapy is associated with reduced depressive symptoms 12 months post percutaneous coronary intervention.* **J Affect Disord.** 2012 Feb;136(3):751-7.
  6. de Mulder M, **Oemrawsingh RM**, Stam F, Boersma E, Umans VA. *Comparison of diagnostic criteria to detect undiagnosed diabetes in hyperglycaemic patients with acute coronary syndrome.* **Heart.** 2012 Jan;98(1):37-41.
  5. de Boer SP, Lenzen MJ, **Oemrawsingh RM**, Simsek C, Duckers HJ, van der Giessen WJ, Serruys PW, Boersma E. *Evaluating the 'all-comers' design: a comparison of participants in two 'all-comers' PCI trials with non-participants.* **Eur Heart J.** 2011 Sep;32(17):2161-7.
  4. **Oemrawsingh RM**, Lenderink T, Akkerhuis KM, Heeschen C, Baldus S, Fichtlscherer S, Hamm CW, Simoons ML, Boersma E; CAPTURE investigators. *Multimarker risk model containing troponin-T, interleukin 10, myeloperoxidase and placental growth factor predicts long-term cardiovascular risk after non-ST-segment elevation acute coronary syndrome.* **Heart.** 2011 Jul;97(13):1061-6.
  3. de Mulder M, Umans VA, Stam F, Cornel JH, **Oemrawsingh RM**, Boersma E. *Intensive management of hyperglycaemia in acute coronary syndromes. Study design and rationale of the BIOMArCS 2 glucose trial.* **Diabet Med.** 2011 Oct;28(10):1168-75.
  2. de Mulder M, **Oemrawsingh RM**, Stam F, Boersma E, Umans VA. *Current management of hyperglycemia in acute coronary syndromes: a national Dutch survey.* **Crit Pathw Cardiol.** 2009 Jun;8(2):66-70; quiz 71.
  1. **Oemrawsingh RM**, Akkerhuis KM, Boersma E. *Tailor-made therapy for the prevention of acute coronary syndromes: future role of biomarkers in risk stratification and disease management.* **Expert Rev Cardiovasc Ther.** 2008 Apr;6(4):435-7.